Abstract
Background: The societal costs of Alzheimer’s Disease (AD) are enormous and pose a great challenge for the health and social care in any society. It is of vital importance to develop and identify cost effective treatment. The aim of the study was to present a hypothetical economic model of Disease Modifying Treatment (DMT) in AD.
Methods: A 20 year Markov cohort model of DMT was constructed, based on Swedish care conditions. States and progression were defined according to the Mini Mental State Examination (MMSE). Epidemiological studies of incidence of dementia, prevalence and costs of Mild Cognitive Impairment (MCI) and AD as well as conversion studies of MCI and demographic statistics were used as inputs in the model. Results: Total costs were 113,797 million SEK for patients treated with DMT vs 88,562 million SEK for untreated patients. The corresponding gained QALYs were 529,945 and 450,307 respectively, giving an incremental cost effectiveness ratio of 293,002 SEK/QALY in the base option. Survival in the model was 8.72 years with DMT and 7.77 years for untreated. With an assumed Willingness to pay (WTP) of 600,000 SEK (about 86,200 US$ and 62,000 €) per gained QALY, the model indicated cost effectiveness with DMT. The sensitivity analysis implied no cost savings with DMT, but most options indicated cost effectiveness vs. the chosen WTP. Conclusion: The main reasons for the higher costs with DMT were the costs of DMT itself and the prolonged survival with DMT. Even if costs increase with DMT, the model indicates cost effectiveness.Keywords: Alzheimer’s disease, dementia, cholinesterase inhibitors, mortality
Current Alzheimer Research
Title:Mortality and Treatment Costs have a Great Impact on the Cost- Effectiveness of Disease Modifying Treatment in Alzheimer’s Disease - A Simulation Study
Volume: 10 Issue: 2
Author(s): Anders Skoldunger, Kristina Johnell, Bengt Winblad and Anders Wimo
Affiliation:
Keywords: Alzheimer’s disease, dementia, cholinesterase inhibitors, mortality
Abstract: Background: The societal costs of Alzheimer’s Disease (AD) are enormous and pose a great challenge for the health and social care in any society. It is of vital importance to develop and identify cost effective treatment. The aim of the study was to present a hypothetical economic model of Disease Modifying Treatment (DMT) in AD.
Methods: A 20 year Markov cohort model of DMT was constructed, based on Swedish care conditions. States and progression were defined according to the Mini Mental State Examination (MMSE). Epidemiological studies of incidence of dementia, prevalence and costs of Mild Cognitive Impairment (MCI) and AD as well as conversion studies of MCI and demographic statistics were used as inputs in the model. Results: Total costs were 113,797 million SEK for patients treated with DMT vs 88,562 million SEK for untreated patients. The corresponding gained QALYs were 529,945 and 450,307 respectively, giving an incremental cost effectiveness ratio of 293,002 SEK/QALY in the base option. Survival in the model was 8.72 years with DMT and 7.77 years for untreated. With an assumed Willingness to pay (WTP) of 600,000 SEK (about 86,200 US$ and 62,000 €) per gained QALY, the model indicated cost effectiveness with DMT. The sensitivity analysis implied no cost savings with DMT, but most options indicated cost effectiveness vs. the chosen WTP. Conclusion: The main reasons for the higher costs with DMT were the costs of DMT itself and the prolonged survival with DMT. Even if costs increase with DMT, the model indicates cost effectiveness.Export Options
About this article
Cite this article as:
Skoldunger Anders, Johnell Kristina, Winblad Bengt and Wimo Anders, Mortality and Treatment Costs have a Great Impact on the Cost- Effectiveness of Disease Modifying Treatment in Alzheimer’s Disease - A Simulation Study, Current Alzheimer Research 2013; 10 (2) . https://dx.doi.org/10.2174/1567205011310020011
DOI https://dx.doi.org/10.2174/1567205011310020011 |
Print ISSN 1567-2050 |
Publisher Name Bentham Science Publisher |
Online ISSN 1875-5828 |
![](/images/wayfinder.jpg)
- Author Guidelines
- Bentham Author Support Services (BASS)
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
Non-Ceruloplasmin Copper as a Stratification Biomarker of Alzheimer’s Disease Patients: How to Measure and Use It
Current Alzheimer Research Clinical and Pharmacological Aspects of Inflammatory Demyelinating Diseases in Childhood: An Update
Current Neuropharmacology Administration of Exogenous Surfactant and Cytosolic Phospholipase A2α Inhibitors may Help COVID-19 Infected Patients with Chronic Diseases
Coronaviruses Roles of p75NTR in Maintaining Brain Hemostasis and the Implications for p75NTR-targeted Therapies
Current Alzheimer Research Strain Specificity and Drug Resistance in Anti-Prion Therapy
Current Topics in Medicinal Chemistry Estrogen Receptors as Targets for Drug Development for Breast Cancer, Osteoporosis and Cardiovascular Diseases
Current Cancer Drug Targets Music Therapy for Individuals with Dementia: Areas of Interventions and Research Perspectives
Current Alzheimer Research Old Friends in New Constellations - the Hematopoetic Growth Factors G-CSF, GMCSF, and EPO for the Treatment of Neurological Diseases
Current Medicinal Chemistry Expression and Functions of LRP-2 in Central Nervous System: Progress in Understanding its Regulation and the Potential Use for Treatment of Neurodegenerative Diseases
Immunology, Endocrine & Metabolic Agents in Medicinal Chemistry (Discontinued) Conference Report: 6<sup>th</sup> Clinical Trials on Alzheimer’s Disease (CTAD) Conference, Nov 14-16, 2013, The Westin San Diego Gaslamp Quarter Hotel, San Diego, CA, USA
CNS & Neurological Disorders - Drug Targets Use of Benzodiazepines and Haloperidol Among Orthopedic Patients in Postoperative Delirium. A Systematic Review
Current Psychopharmacology Combining in vitro and in silico Approaches to Find New Candidate Drugs Targeting the Pathological Proteins Related to the Alzheimer's Disease
Current Neuropharmacology Novel Pyrimidine based Semicarbazones: Confirmation of Four Binding Site Pharmacophoric Model Hypothesis for Antiepileptic Activity
Central Nervous System Agents in Medicinal Chemistry Lipid-Based Nanocarriers for CNS-Targeted Drug Delivery
Recent Patents on CNS Drug Discovery (Discontinued) Medicinal Chemistry of Potassium Channel Modulators: An Update of Recent Progress (2011-2017)
Current Medicinal Chemistry Actions of Adjunctive Nutritional Antioxidants in Periodontitis and Prevalent Systemic Inflammatory Diseases
Endocrine, Metabolic & Immune Disorders - Drug Targets Modulation of Alzheimers Amyloidosis by Statins: Mechanisms of Action
Current Medicinal Chemistry - Immunology, Endocrine & Metabolic Agents The Development of Topically Acting Carbonic Anhydrase Inhibitors as Antiglaucoma Agents
Current Topics in Medicinal Chemistry Removing Protein Aggregates: The Role of Proteolysis in Neurodegeneration
Current Medicinal Chemistry How Immune-inflammatory Processes Link CNS and Psychiatric Disorders: Classification and Treatment Implications
CNS & Neurological Disorders - Drug Targets